Aegle Therapeutics Corp

Woburn, MA · Founded 2019 · CIK 0001797825 · Biotech · Private

Extracellular vesicle (EV) therapies for regenerative medicine

aegletherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$6.7M
3 Form D · Aug 2026
2 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,010,000
Private capital raisedForm D · SEC$455,695
Private capital raisedForm D · SEC$2,277,698
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1218Willowcroft Pharm Inc—$5.0M
1219Valanbio Therapeutics Inc—$121K
1220IMMUNOQ THERAPEUTICS INC.——
1221Aegle Therapeutics Corp—$6.7M
1222Intelligent Therapeutics, Inc.—$100K
1223CHEMITOPE GLYCOPEPTIDE, LLC—$100K
1224QENTOROS LLC—$605K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • Evangelos BadiavasDirector · Executive Officer
  • Elona BaumDirector
  • Scott BraunsteinDirector
  • Shelley HartmanDirector · Executive Officer
  • Leon MoulderDirector
  • Leon Moulder, Jr.Director
  • Steve O'HaraDirector
  • Robert RyanDirector
  • David SchimelDirector
  • Mikio TanjiDirector
  • Robert Williamson, Jr.Director · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.